[Federal Register: October 7, 2004 (Volume 69, Number 194)]
[Notices]
[Page 60155-60156]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr07oc04-42]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-04-0588]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-498-1210 or
send comments to Seleda Perryman, CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS-E11, Atlanta, GA 30333 or send an e-mail
to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Evaluating the Impact of Lymphedema and a Lymphedema Management
Intervention for Women with Lymphatic Filariasis: Understanding Issues
Related to Quality of Life (OMB No. 0920-0588)--Extension--National
Center for Infectious Diseases (NCID), Centers for Disease Control and
Prevention (CDC).
Lymphatic filariasis, a mosquito-transmitted parasitic disease
affecting over 120 million people, is the second leading cause of
permanent disability worldwide. Globally, lymphatic filariasis causes
debilitating genital disease in an estimated 25 million men and
lymphedema or elephantiasis of the leg in 15 million people, mostly
women in poverty stricken countries. The World Health Organization
(WHO) recently identified community management of chronic lymphedema as
one of the top twenty lymphatic filariasis research priorities. Recent
advances in the management of chronic lymphedema include a prescribed
hygiene and wound care intervention. This intervention has shown
promising results in: (1) Preventing bacterial infections thus reducing
acute attacks; (2) anecdotally improving overall quality of life; (3)
alleviating pain; (4) and preventing further suffering.
The data gathered from this study will assist CDC in the
development, monitoring and evaluation of morbidity control programs,
and the provision of technical assistance to collaborating countries in
the Global Alliance to Eliminate Lymphatic Filariasis. The data
collected by this study will allow CDC to determine directly from
affected women such information as knowledge and attitudes related to
disease and secondary infections; perceptions of women related to
disease transmission; health seeking practices; and current self-care
of women who are not under care as well as those who are. This
formative data will be used to assist the Ministry of Health in each
country to develop new lymphedema management programs and modify
current public health educational campaigns to recruit affected
populations into treatment. The data will also provide the basis for
culturally-tailored public health education strategies that increase
the community's as well women's knowledge of lymphatic filariasis,
address barriers to health care seeking, debunk myths surrounding
disease and morbidity, utilize traditional health care practitioners,
train community health care workers in management techniques, inform
programs of the psychological, physical, and emotional needs that women
have, and other issues identified in research findings.
In addition, the data findings will also be used on a global level
(in collaboration with WHO, PAHO, the Liverpool School of Medicine,
Emory University, and others) to develop process and outcome indicators
for evaluating and monitoring treatment programs at the clinic-level,
community-level and home-level. As new programs are initiated, critical
evaluation measures are needed to measure the effectiveness of these
programs to avoid spending money on ineffective strategies.
Operationally this data will allow us to develop a public health
strategy for women with disease and their communities that include the
regimen of meticulous local hygiene to the affected areas. It will also
allow us to develop critical evaluation indicators to ensure
appropriate program monitoring so that information will be immediately
available for assessment by both the affected countries and the donor
agencies supporting program activities. Data will be widely
disseminated in reports, presentations, and professional peer-reviewed
publications to persons who work in prevention of this disease. There
is no cost to respondents.
Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Questionnaires Number of responses per per response Total burden
respondents respondent (in hrs.) hours
----------------------------------------------------------------------------------------------------------------
Qualitative Interviews.......................... 50 1 30/60 25
Quantitative Survey............................. 200 1 1 200
-----------------
Total....................................... 250 .............. .............. 225
----------------------------------------------------------------------------------------------------------------
[[Page 60156]]
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 04-22550 Filed 10-6-04; 8:45 am]
BILLING CODE 4163-18-U